TY - JOUR
T1 - Does covid-19 vaccination warrant the classical principle “ofelein i mi vlaptin”?
AU - Doulberis, Michael
AU - Papaefthymiou, Apostolis
AU - Kotronis, Georgios
AU - Gialamprinou, Dimitra
AU - Soteriades, Elpidoforos S.
AU - Kyriakopoulos, Anthony
AU - Chatzimichael, Eleftherios
AU - Kafafyllidou, Kyriaki
AU - Liatsos, Christos
AU - Chatzistefanou, Ioannis
AU - Anagnostis, Paul
AU - Semenin, Vitalii
AU - Ntona, Smaragda
AU - Gkolia, Ioanna
AU - Papazoglou, Dimitrios David
AU - Tsinonis, Nikolaos
AU - Papamichos, Spyros
AU - Kirbas, Hristos
AU - Zikos, Petros
AU - Niafas, Dionisios
AU - Kountouras, Jannis
N1 - Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/3
Y1 - 2021/3
N2 - The current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic war-rants an imperative necessity for effective and safe vaccination, to restrain Coronavirus disease 2019 (COVID-19) including transmissibility, morbidity, and mortality. In this regard, intensive medical and biological research leading to the development of an arsenal of vaccines, albeit incomplete pre-conditioned evaluation, due to emergency. The subsequent scientific gap raises some concerns in the medical community and the general public. More specifically, the accelerated vaccine development downgraded the value of necessary pre-clinical studies to elicit medium-and long-term beneficial or harmful consequences. Previous experience and pathophysiological background of coronaviruses’ infections and vaccine technologies, combined with the global vaccines’ application, underlined the obligation of a cautious and qualitative approach, to illuminate potential vaccination-related adverse events. Moreover, the high SARS-CoV-2 mutation potential and the already aggregated genetical alterations provoke a rational vagueness and uncertainty concerning vaccines’ efficacy against dominant strains and the respective clinical immunity. This review critically summarizes existing evidence and queries regarding SARS-CoV-2 vaccines, to motivate scientists’ and clinicians’ interest for an optimal, individualized, and holistic management of this unprecedented pandemic.
AB - The current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic war-rants an imperative necessity for effective and safe vaccination, to restrain Coronavirus disease 2019 (COVID-19) including transmissibility, morbidity, and mortality. In this regard, intensive medical and biological research leading to the development of an arsenal of vaccines, albeit incomplete pre-conditioned evaluation, due to emergency. The subsequent scientific gap raises some concerns in the medical community and the general public. More specifically, the accelerated vaccine development downgraded the value of necessary pre-clinical studies to elicit medium-and long-term beneficial or harmful consequences. Previous experience and pathophysiological background of coronaviruses’ infections and vaccine technologies, combined with the global vaccines’ application, underlined the obligation of a cautious and qualitative approach, to illuminate potential vaccination-related adverse events. Moreover, the high SARS-CoV-2 mutation potential and the already aggregated genetical alterations provoke a rational vagueness and uncertainty concerning vaccines’ efficacy against dominant strains and the respective clinical immunity. This review critically summarizes existing evidence and queries regarding SARS-CoV-2 vaccines, to motivate scientists’ and clinicians’ interest for an optimal, individualized, and holistic management of this unprecedented pandemic.
KW - COVID-19
KW - Hippocrates
KW - Ofelein i mi vlaptin
KW - Primum non nocere
KW - SARS-COV-2
KW - Vac-cine
KW - Vaccination
UR - http://www.scopus.com/inward/record.url?scp=85103162087&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85103162087&partnerID=8YFLogxK
U2 - 10.3390/medicina57030253
DO - 10.3390/medicina57030253
M3 - Review article
C2 - 33803295
AN - SCOPUS:85103162087
SN - 1010-660X
VL - 57
JO - Medicina
JF - Medicina
IS - 3
M1 - 253
ER -